Opendata, web and dolomites

PET3D SIGNED

PET Imaging in Drug Design and Development

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "PET3D" data sheet

The following table provides information about the project.

Coordinator
LOUGHBOROUGH UNIVERSITY 

Organization address
address: ASHBY ROAD
city: LOUGHBOROUGH
postcode: LE11 3TU
website: www.lboro.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://www.pet3d.eu/
 Total cost 3˙912˙634 €
 EC max contribution 3˙901˙247 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2015
 Funding Scheme MSCA-ITN-ETN
 Starting year 2016
 Duration (year-month-day) from 2016-06-01   to  2020-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    LOUGHBOROUGH UNIVERSITY UK (LOUGHBOROUGH) coordinator 165˙187.00
2    THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN UK (ABERDEEN) participant 620˙515.00
3    UNIVERSITETET I BERGEN NO (BERGEN) participant 572˙550.00
4    STICHTING VUMC NL (AMSTERDAM) participant 510˙748.00
5    VRIJE UNIVERSITEIT BRUSSEL BE (BRUSSEL) participant 501˙120.00
6    WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER DE (MUENSTER) participant 498˙432.00
7    ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOMATERIALES- CIC biomaGUNE ES (SAN SEBASTIAN) participant 495˙745.00
8    IMANOVA LIMITED UK (LONDON) participant 273˙287.00
9    ASTRAZENECA AB SE (SODERTAELJE) participant 263˙659.00
10    STICHTING VU NL (AMSTERDAM) participant 0.00

Map

 Project objective

The drug development strategy currently pursued by the pharmaceutical industry worldwide is inefficient and unsustainable for the health care system. To keep the latter affordable, drug development should become more efficient and drug treatment should become more “personalized” and “rationalized”. Molecular imaging can play a pivotal role in changing the landscape of drug design/development and improving the health care system. Positron Emission Tomography (PET) imaging, in particular, is the technology that has the potential to lead this fundamental innovation by providing at a much earlier stage reliable answers to key questions emerging during the care cycle: what and where is the disease? Is the disease accurately targeted by the therapy? Is the treatment effective? By answering the questions above, PET imaging has the capacity to render much more effectively the transition from pre-clinical to clinical phase, and to strongly facilitate the development of better drugs at an earlier stage and in a much more sustainable manner. The main obstacle to this change of paradigm in drug design and development is the lack of suitably trained translational scientists directly involved in PET imaging and imaging scientists with high-profile training in chemistry and PET-radiochemistry, which is particularly dramatic in Europe. This consortium is ideally suited to fill this gap, by providing top-quality training to the next generation of translational PET imaging scientists who will play a key role in shaping the future of drug design and development. The PET3D ETN will focus on 15 cutting-edge research projects in the 3 main therapeutic areas (oncology, cardiovascular, central nervous system) that will be conducted by 15 ESRs at 8 European beneficiary Institutions, 6 academic (all having a PET center on site) and 2 non-academic (one with a PET center on site and one big pharmaceutical company) representing the drug design and development terminus of the project.

 Deliverables

List of deliverables.
Award of PhD degree to ESR15 Documents, reports 2020-03-06 15:37:29
PET3D website Websites, patent fillings, videos etc. 2019-08-30 14:12:01

Take a look to the deliverables list in detail:  detailed list of PET3D deliverables.

 Publications

year authors and title journal last update
List of publications.
2018 Bastian Zinnhardt, Maximilian Wiesmann, Lisa Honold, Cristina Barca, Michael Schäfers, Amanda J Kiliaan, Andreas H Jacobs
In vivo imaging biomarkers of neuroinflammation in the development and assessment of stroke therapies - towards clinical translation
published pages: 2603-2620, ISSN: 1838-7640, DOI: 10.7150/thno.24128
Theranostics 8/10 2019-08-30
2018 Ryan A. Bragg, Malvika Sardana, Markus Artelsmair, Charles S. Elmore
New trends and applications in carboxylation for isotope chemistry
published pages: , ISSN: 0362-4803, DOI: 10.1002/jlcr.3633
Journal of Labelled Compounds and Radiopharmaceuticals 2019-08-30
2019 Markus Artelsmair, Patricia Miranda-Azpiazu, Lee Kingston, Jonas Bergare, Magnus Schou, Andrea Varrone, Charles S. Elmore
Synthesis, 3 H-labelling and in vitro evaluation of a substituted dipiperidine alcohol as a potential ligand for chemokine receptor 2
published pages: , ISSN: 0362-4803, DOI: 10.1002/jlcr.3731
Journal of Labelled Compounds and Radiopharmaceuticals 2019-08-30

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PET3D" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PET3D" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

DISTINCT (2019)

Dementia: Intersectorial Strategy for Training and Innovation Network for Current Technology (DISTINCT)

Read More  

BIGMATH (2018)

Big Data Challenges for Mathematics

Read More  

POLISS (2019)

Policies for Smart Specialisation

Read More